You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The closing range uses available history since Jul 23, 2026; less than a full year is stored.
Alvotech received FDA approval on October 20, 2026 for a new SIMLANDI® manufacturing process that more than doubles drug substance output per batch while maintaining product quality, safety and efficacy.
Alvotech and Advanz Pharma submitted a European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg, described as the first regulatory submission worldwide for that biosimilar. The application is a line extension to Mynzepli’s existing European marketing authorization.
Alvotech and LOTTE Biologics entered a long-term manufacturing partnership for drug substance covering multiple antibody biosimilars at a Syracuse facility with 40,000 liters of bioreactor capacity. Commercial supply requires technology transfer, manufacturing qualification and regulatory approvals.
On October 5, 2026, the U.S. Food and Drug Administration approved Alvotech’s SIMLANDI® to use a second production suite at its Reykjavik facility, doubling drug substance manufacturing capacity for U.S. supply and confirming resolution of inspection-related matters.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALVOW
this stock
Alvotech
|
$1.73B | — | — | — | — |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$67.16B | +34.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$55.28B | +12.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.72B | +36.5% | +4.3% | 96.8 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Alvotech received FDA approval on October 20, 2026 for a new SIMLANDI® manufacturing process that more than doubles drug substance output per batch while maintaining product quality, safety and efficacy.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALVOW | -24.9% | -63.2% | — | -42.5% | — |
| SPY | -2.7% | -5.6% | -0.5% | -2.7% | +7.8% |
| vs SPY | -22.2% | -57.6% | — | -39.8% | — |
